IMMUNOVO
Immunovo BV is a Dutch private biotechnology company, based in ‘s-Hertogenbosch, engaged in the discovery and clinical development of immunotherapeutics in the field of oncology. The key priority for Immunovo is on its proprietary Immune Activation System (IAS) based on combining synthetic peptide antigens with a novel immune stimulant (adjuvant).
IMMUNOVO
Industry:
Biotechnology Pharmaceutical
Founded:
2009-01-01
Address:
's-hertogenbosch, Noord-Brabant, The Netherlands
Country:
The Netherlands
Website Url:
http://www.immunovo.com
Total Employee:
1+
Status:
Active
Contact:
+31 (0) 73 – 627 4520
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Content Delivery Network Facebook Sharer OpenResty AdBlock Acceptable Ads Sharktech Shark Tech
Similar Organizations
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
EpiVax
EpiVax is an immunology company developing comprehensive analytical capabilities in the field of computational immunology.
Current Employees Featured
Investors List
Biox Biosciences
Biox Biosciences investment in Seed Round - Immunovo
Lupus Ventures
Lupus Ventures investment in Seed Round - Immunovo
More informations about "Immunovo"
ImmuNovX Biotech
ImmuNovX Biotech is an early-stage company whose mission is to develop the groundbreaking technology . we call LR3N-CS, a platform that allows rapid, large-scale treatment of DNA pathogens to . generate a novel class of vaccines. …See details»
Immunovo - Crunchbase Company Profile & Funding
Immunovo BV is a Dutch private biotechnology company, based in ‘s-Hertogenbosch, engaged in the discovery and clinical development of immunotherapeutics in the field of oncology.See details»
Immunovo Company Profile - Craft
Immunovo is a biotechnology company engaged in the discovery and clinical development of immunotherapeutics in the field of oncology. It offers the Immune Activation System (IAS) based on combining synthetic peptide antigens with an immune stimulant (adjuvant).See details»
Immunovo - Products, Competitors, Financials, Employees, …
Developer of methods in immunotherapy with insights in oncology. Use the CB Insights Platform to explore Immunovo's full profile.See details»
Contact Us - ImmuNovX Biotech
ImmuNovX Biotech, LLC. 1950 Butler Pike, Conshohocken, Pennsylvania 19428, United States. 610-941-4750See details»
ImmuNovX Biotech - PitchBook
ImmuNovX Biotech is headquartered in Conshohocken, PA. What industry is ImmuNovX Biotech in? ImmuNovX Biotech’s primary industry is Drug Discovery. Is ImmuNovX Biotech a private or public company? ImmuNovX Biotech is a Private company. What is ImmuNovX Biotech’s …See details»
ImmuNovX Biotech, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ImmuNovX Biotech, LLC of Plymouth Meeting, PA. Get the latest business insights from Dun & Bradstreet.See details»
Immunovx Biotech Company Profile -Sales, Contacts, Competitors …
Immunovx Biotech is in the Business Activities At Non-Commercial Site industry within the Business Services sector and has been in business for approximately 2 years.See details»
ImmuNovX Biotech | Life Sciences PA
ImmuNovX Biotech is an early-stage company whose mission is to develop the groundbreaking technology we call LR3N-CS, a platform that allows rapid, large-scale treatment of DNA pathogens to generate a novel class of vaccines. The LR3N-CS platform technology …See details»
Meet the Spring 2024 Science Inc. Cohort: ImmuNoVx Biotech
This transformation injects a fresh wave of energy into our organization, highlighting our audacity, passion for science, and the dynamism of our teams. #4PPharma # ...See details»
Immunovo B.V. - BioCentury Company Profiles - BCIQ
Jan 17, 2011 Immunovo B.V. - BioCentury Company Profiles for the biopharma industrySee details»
Immunovo - Crunchbase
Immunovo is operate as a biotechnology company to develop technology to create immunotherapeutic drugsSee details»
Welcome to the new ImmuNovo websit - de-wolff.nl
This website tells you everything you need to know about ImmunoNovo and especially about the development of our therapeutic vaccines. Besides you can also find here (inter)national news on immunotherapy, a regular fresh update of the developments within ImmuNovo and the …See details»
Immunovo - Company Profile - Tracxn
Nov 24, 2023 Immunovo - Mid-stage, Dutch private biotechnology company focusing on discovery and clinical development of immunotherapeutics in Oncology.. This company is not active anymore. Raisedfunding over 1 round from 1 investor. Immunovo has 2799 competitors.See details»
New Biotechnology Company: Immunovo BV - Immunovo BV …
Apr 29, 2010 Immunovo BV, a new biotechnology company developing a novel technology platform for the creation of a new generation of immunotherapeutics, has secured seed funding from Biox Biosciences BV and L ...See details»
Immunovo - VentureRadar
Immunovo VentureRadar profile. Find out more about Immunovo, Vaccines.See details»
Inovo Biotech Inc. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Inovo Biotech Inc. of Toronto, ON. Get the latest business insights from Dun & Bradstreet.See details»
Immunovo BV- A New Biotechnology Company is Announced
Apr 28, 2010 S-HERTOGENBOSCH, The Netherlands, April 27, 2010 /PRNewswire/ -- Immunovo BV, a new biotechnology company looking to combine novel methods in immunotherapy with the most recent insights in oncology to develop novel therapeutics, secures seed funding from Dutch venture capital firms.See details»
Immunovo - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Apr 28, 2010: Seed Round - Immunovo . 2: obfuscated. obfuscated — Investors. Edit Investors Section. Number of …See details»
Immunova 2025 Company Profile: Valuation, Funding & Investors
Immunova General Information Description. Developer of a drug development platform intended to innovate therapeutics for cancer patients. The company's platform stimulates T-cell proliferation, increasing the presence of tumour infiltrating lymphocytes while blocking a key mediator of immunosuppression in the tumour microenvironment, delivers desired …See details»